Neuropharmacology lies at the interface between two rapidly-advancing disciplines: neuroscience and pharmacology. For at least a generation, the discipline of neuropharmacology has enjoyed pride of place in the research interests of Pharmacology and Therapeutics at McGill.
Currently, almost one half of core departmental members conduct neuropharmacological research. These individuals run well-funded research groups, each with a strong track record of high-quality research and training. The internationally-recognized research covers a vast gamut
Following is a list of faculty members currently conducting research. Follow the links to read additional information about each investigator's research interests, publications and the work being done in their laboratory.
E-mail: guillermina.almazan [at] mcgill.ca ( )
Research: Molecular Neuropharmacology
Central nervous system development with emphasis on myelination; molecular and cellular signals that regulate the growth of oligodendrocytes and their progenitors; critical interactions of oligodendrocytes with neurons and astrocytes; signaling mechanisms in oligodendrocytes. Relevance for demyelinating diseases such as Multiple Sclerosis.
E-mail: daniel.bernard [at] mcgill.ca
Research: Molecular endocrinology, reproductive physiology, intracellular signaling, transcriptional regulation
Signal transduction mechanisms through which members of the transforming growth factor β (TGF β) superfamily regulate synthesis of pituitary hormones, in particular follicle-stimulating hormone (FSH). This research may identify causes and treatments for some forms of infertility and will highlight novel contraceptive targets.
Phone: 514-398-1581 (office) 2513 (lab)
E-mail: derek.bowie [at] mcgill.ca
Lab Web Site: http://www.medicine.mcgill.ca/pharma/dbowielab
Research: Synaptic Transmission, Neurodevelopment & its Disorders, Epilepsy, Glaucoma
Structure/function analysis of ionotropic glutamate receptors and GABA-A receptors. These receptors are implicated in disease states associated with postnatal development (e.g. Autism, Schizophrenia), cerebral insult (e.g. Stroke, Epilepsy) and aging disorders (e.g. Alzheimer's disease, Parkinsonism).
Phone: 514-398-3616 ext. 1 (office) or ext. 2 (lab)
E-mail: paul.clarke [at] mcgill.ca
Lab Web Site: http://www.mcgill.ca/pharma/facultystaff/faculty/paul-clarke
Research: How drugs affect brain function.
Mechanisms by which drugs affect brain function, specifically the dopaminergic system; mechanisms by which drugs such as nicotine, amphetamine and cocaine create addiction. Approaches include a combination of neurochemical and behavioural tests in rats, e.g. intravenous self-administration, conditioned place preference, combined with autoradiographic and immunohistochemical analyses.
E-mail: claudio.cuello [at] mcgill.ca
Lab Web Site: http://www.medicine.mcgill.ca/pharma/cuellolab/
Research: Cellular and Molecular Neuropharmacology
Degenerative and regenerative processes in the CNS with emphasis on aging and Alzheimer’s disease. The laboratory utilizes and develops transgenic animal models presenting features of the AD neuropathology. The lab makes comparative neurochemical studies between post-mortem human brain samples and transgenic models. The research is of a multidisciplinary nature ranging from molecular approaches, tissue culture, neurochemistry, confocal and electron microscopy immunocytochemistry to cognitive studies. The lab focuses on early aspects of the Alzheimer’s pathology therapeutics such pre-plaque inflammatory processes and deregulation of cell signaling pathways and trophic factor metabolism.
E-mail: dusica.maysinger [at] mcgill.ca
Lab Web Site: http://www.medicine.mcgill.ca/pharma/dmaysingerlab/
Research: Nanomedicine – Nanodelivery Systems, Subcellular Fate of nanoparticles & nanoparticles in Medicine
Investigations of mechanisms of drug action; non-invasive imaging at single cell level and in experimental animal models-signal transduction pathways in glia and neurons. Combinatorial cell-and drug-based therapeutic interventions in conjunction with nano-delivery systems.
E-mail: anne.mckinney [at] mcgill.ca
Research: Excitatory synapses in the CNS
Mechanisms involved in development and maintenance of excitatory synapses in the CNS, during physiological and pathological conditions, such as epilepsy and mental retardation; specific emphasis on structure and function of dendritic spines and their synapses in the hippocampus, a brain region involved in learning and memory. Use of organotypic cultures, real-time 3-dimensional confocal laser scanning microscopy and advanced electrophysiological techniques.
Life Sciences Complex, Bellini
3649 Prom. Sir-William-Osler
Montreal, QC, H3G 0B1
Research interests include (i) understanding the APP biology, i.e., to unravel the protein network and the mechanisms involved in Aβ generation by structural and functional analyses, and (ii) investigating the molecular events of amyloid aggregation, gain of toxicity, and the causes of neuronal dysfunction. Our primary aim is to identify novel targets to develop pharmacological strategies for prevention and therapy.
E-mail: alfredo.ribeirodasilva [at] mcgill.ca
Research: Neuroscience (Neurocytology, Neuropharmacology)
Mechanisms underlying chronic pain states, both in the central and peripheral nervous systems; particular emphasis on arthritis and neuropathic pain models. Methods used include: immunocytochemistry at the light and electron microscopic levels, animal behavior testing, and neurochemistry. Also collaborates with Dr. Cuello in the study of the effects of aging on the structure and function of the neocortex.
Position: Associate Professor
Phone: 514-340-8222 ext. 5055
E-mail: uri.saragovi [at] mcgill.ca
Research: Receptor Biology Structure- Function Relationships and Signal Transduction Events
Macromolecular structure/function relationships in receptor-ligand interactions; development of mimics of antibodies, cellular receptors and polypeptide growth factors (antagonists and agonists); use of these ligands for in vivo imaging and tumor localization; selective delivery of therapeutic agents can be selectively delivered to the target cell; extension of the concept of ligand mimicry to develop functional ligands.